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Background: Isoquercitrin, a flavonoid compound that is widely distributed in medicinal and dietary plants,
possesses many biological activities, including inhibition of adipocyte differentiation. In this study, we investigated
the effect of isoquercitrin on lipid accumulation and its molecular mechanisms in rat hepatoma H4IIE cells.
Methods: To investigate the effect of isoquercitrin on lipid accumulation, H4IIE cells were induced by FFA and the
total lipid levels were detected by Oil Red O staining. Furthermore, The protein levels of AMPK and acetyl-CoA
carboxylase (ACC), the gene expressions of transcriptional factor, lipogenic genes, and adiponectin receptor 1
(AdipoR1) were analyzed by Western blotting and quantitative real-time PCR. To further confirm the pathway of
isoquercitrin-mediated hepatic lipid metabolism, H4IIE cells were treated with an AMPK inhibitor and AdipoR1 siRNA.
Results: Isoquercitrin significantly enhances AMPK phosphorylation, downregulates sterol regulatory element binding
protein transcription factor 1 (SREBP-1) and fatty acid synthase (FAS) gene expressions. Pretreatment with AMPK
inhibitor, significantly decreased the AMPK phosphorylation and increased FAS expression stimulated by isoquercitrin.
Isoquercitrin might also upregulate the expression of AdipoR1 dose-dependently via AMPK in the presence of an AMPK
inhibitor and AdipoR1 siRNA.
Conclusions: Isoquercitrin appears to regulate AMPK activation, thereby enhancing AdipoR1 expression,
suppressing SREBP-1 and FAS expressions, and resulting in the regulation of lipid accumulation. These results
suggest that isoquercitrin is a novel dietary compound that can be potentially be used to prevent lipid metabolic
disorder and nonalcoholic fatty liver disease.
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Adenosine monophosphate-activated protein kinase (AMPK)
has been recognized as a master regulator of hepatic
metabolism. Its activation results in an increase in fatty
acid oxidation and suppression of fatty acid synthesis
via inactivation of acetyl-CoA carboxylase (ACC). It in-
hibits the lipogenic gene expression of fatty acid synthase
(FAS) by decreasing the action of transcription factors [1].
Sterol regulatory element binding protein 1 (SREBP-1) is
the most important transcription factor regulating the ex-
pression of lipogenic enzymes, including ACC and FAS.* Correspondence: thliu@vip.163.com; gaoming@mukogawa-u.ac.jp
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reproduction in any medium, provided the orMany studies have suggested that increased levels of
SREBP-1 are closely associated with fatty liver in obese
animal models [2]. Meanwhile, a previous report has
shown that SREBP-1 is mediated by AMPK [3]. Therefore,
AMPK plays a key role in fatty acid metabolism in the
liver and in whole body lipid metabolism.
Lipid metabolic disorder refers to a disruption in lipid
metabolism in which there are excessive serum levels of
lipids and lipoprotein lipids. This disorder has escalated
into a major worldwide public health problem, and it is a
critical risk factor for metabolic syndromes, such as insu-
lin resistance, type 2 diabetes mellitus, and cardiovascular
diseases [4]. Nonalcoholic fatty liver disease (NAFLD) de-
velops when a large amount of lipid is deposited in hepa-
tocytes, and it is tightly associated with lipid metabolic
disorder [5]. Untreated NAFLD may progress to moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lar carcinoma, and, consequently, influence other body
systems to cause atherosclerosis, type 2 diabetes, and
hypertension [6]. Therefore, it is essential to identify
ways to prevent fatty liver. Treatment of fatty liver fo-
cuses on inhibition of excessive free fatty acids (FFAs),
either by reducing hepatic lipogenesis or by increasing
oxidation or export.
Recently, adiponectin receptors (AdipoRs) and AMPK
signaling have been recognized as critical regulators of
hepatic lipid metabolism to treat fatty liver. AdipoRs and
AMPK signaling suppress fatty acid synthesis by inacti-
vating ACC and FAS and stimulate fatty acid oxidation.
SREBP-1, a key lipogenic transcription factor, plays a
major role in regulating hepatic lipid metabolism, in-
cluding lipolysis and fatty acid synthesis [7]. Inhibition
of SREBP-1 expression by activating AMPK reduces lipid
accumulation in hepatocytes to ameliorate fatty liver.
Currently, many pharmaceutical chemicals for the treat-
ment of fatty liver, such as insulin sensitizers and lipid-
lowering drugs, have the risk of side effects. In contrast,
natural dietary compounds, which can ameliorate steato-
sis, may have fewer risks. These natural compounds also
play an important role in improving the quality of life
and maintaining health. Therefore, the discovery of food
components that can prevent and treat NAFLD is of
interest and value.
Isoquercitrin (quercetin3-O-b-D-glucopyranoside) is a
natural flavonoid glucoside that is distributed in medi-
cinal and dietary plants, such as vegetables, herbs, and
flowers [8]. Isoquercitrin has been found to have a wide
range of biological properties, such as anti-inflammatory
effects [9]; antioxidant activity, including decreasing
ROS levels and reducing lipid peroxidation both in vivo
and in vitro [10]; neuroprotection; and promotion of
neurite elongation [11]. In particular, a recent study re-
ported that isoquercitrin inhibits adipocyte differenti-
ation of 3 T3-L1 cells via activation of Wnt/β-catenin
signaling [12]. However, it is not clear whether isoquer-
citrin mediates AMPK signaling to result in amelioration
of lipid metabolism in hepatocytes.
Recently, many studies in cell lines and animal models
have examined the ability of food and dietary plant compo-
nents to prevent fatty liver and hepatic steatosis by mediat-
ing hepatic lipid accumulation. Research has focused on
luteolin [13] and anthocyanins [14]. Additionally, studies
have indicated that isoquercitrin may possess the capability
to reduce lipid peroxidation and inhibit adipocyte differen-
tiation. However, it has not been clarified in vitro whether
isoquercitrin regulates the hepatic AMPK pathway, which
plays a critical role in mediating lipid metabolism and fatty
accumulation. In the present study, we investigated the ef-
fects of isoquercitrin on the management of the AMPK
signaling pathway in rat hepatoma H4IIE cells.Methods
Reagents
Isoquercitrin was purchased from the National Institutes
for Food and Drug Control (Beijing, China). Dulbecco’s
modified Eagle’s medium (DMEM) and antibiotic solution
was obtained from Nacalai Tesque (Kyoto, Japan). AMPK
inhibitor, compound C was pucharsed from Santa Cruz
Biotechnology, Inc. (Texas, USA), and 5-aminoimidazole-
4-carboxamide 1-ribofuranoside (AICAR) was purchased
from Cell Signaling Technology, Inc. (Beverly, USA).
Cell culture
Rat hepatoma (H4IIE) cells, which were purchased
from The Japanese Collection of Research Bioresources
Cell Bank (Osaka, Japan), were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% streptomycin/
penicillin (Nacalai Tesque, Kyoto, Japan) at 37°C in a
5% CO2 humidified atmosphere. Cells at 70–80% con-
fluence were exposed to various concentrations of iso-
quercitrin (50, 100, or 200 μM) or to 1 μL dimethyl
sulfoxide (DMSO) as a control for the indicated times.
All of the cells were incubated at 37°C in a 5% CO2 hu-
midified atmosphere.
MTT assay
H4IIE cells were plated at 5000 cells/well in 96-well tissue
culture plates. The indicated concentrations of isoquerci-
trin (0, 50, 100, and 200 μM) dissolved in DMSO were
added and incubated for 72 h. MTT reagent (0.01 ml,
5 mg/ml) was added and incubated in each well for 3 h.
The MTT medium was replaced with 0.1 ml DMSO, and
absorbance was read at 570 nm. Cell viability was calcu-
lated by the absorbance of isoquercitrin-treated cells com-
pared to control cells.
Oil Red O staining and measurement of lipid
accumulation
Oil Red O powder (150 mg) was dissolved in 50 ml of
isopropanol to form a stock solution, which was diluted
with distilled water to 60% of the stock concentration.
After filtration, the supernatant was stored at room
temperature. Subconfluent H4IIE cells were cultured
with the control group (DMSO) and the given concen-
trations of isoquercitrin (50, 100, or 200 μM) in DMEM
for 24 h. Next, the cells were treated with 0.1 mM FFA
for another 24 h to produce lipid accumulation. The cell
layers were washed with phosphate-buffered saline
(PBS), fixed in 10% formalin for 10 min, stained with Oil
Red O dye solution for 20 min at room temperature,
washed with 60% isopropanol to remove unbound dye,
washed with PBS, and then photographed under a
microscope. Subsequently, the Oil Red O stain was
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measured by absorbance at 540 nm.
Western blotting
Confluent cells with or without isoquercitrin were pre-
pared with 100 μl of ice-cold homogenization buffer
containing 50 mM Tris–HCl (pH 7.4), 100 mM NaCl,
1% Nonidet-P40, 0.25% sodium deoxycholate, 0.1% so-
dium dodecyl sulfate (SDS), 1 mM ethylenediaminetetra-
acetic acid (EDTA), 50 mM NaF, 2 mM Na3VO4, 30 mM
sodium pyrophosphate, 2 mM phenylmethanesulfonyl-
fluoride (PMSF), 1 mM benzamidine, 0.02 g/mL trypsin
inhibitor, 0.02 g/mL leupeptin, and 0.02 g/mL aprotinin.
After incubation on ice for 30 min, the lysates were cen-
trifuged at 12,000 rpm for 10 min, and the supernatants
were isolated. Proteins were extracted by boiling in
0.5 mmol/l Tris–HCl, pH 6.8, 20% glycerol, 10% SDS,
0.1% bromophenol blue, and 10% 2-mercaptethanol.
Equal amounts of protein (20 μg) were electrophoresed
on a 7.5–12.5% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) gel at 100 V for 2 h, and
transferred onto polyvinylidene fluoride (PVDF) mem-
branes (Amersham Life Science, Inc., Buckinghamshire,
UK) at 100 mA for 2 h. The membranes were blocked
in Blocking One-P and Blocking One (Nacalai Tesque,
Kyoto, Japan) for 30 min. After blocking, the mem-
branes were incubated overnight at 4°C with the follow-
ing rabbit primary antibodies (at a dilution of 1:1000 in
antibody solution 1 [Toyobo, Osaka, Japan]): p-AMPKα
Thr172, t-AMPKα, p-ACC Ser79, or t-ACC (Cell Signal-
ing Technology, Beverly, USA). The membranes were
then washed with Tris-buffered saline and Tween 20
(TBST) and incubated with horseradish peroxidase-linked
anti-rabbit secondary antibodies (1:10,000) for 1 h at room
temperature. Detection was achieved using Ez Capture ST
(ATTO, Tokyo, Japan) with Chemi-Lumi One Super
(Nacalai Tesque, Kyoto, Japan). Bands were quantified and
scanned using NIH Image. β-Actin was used as an internal
control.
Quantitative real-time PCR
Total RNA was isolated using Sepasol-RNA I Super G
(Nacalai Tesque, Kyoto, Japan). Real-time PCR kits were
from TOYOBO (Tokyo, Japan). RNA (1 μg) from each
sample was reverse-transcribed to cDNA using the Rever-
Tra Ace qPCR RT Kit, according to the manufacturer’s in-
structions (Toyobo). THUNDERBIRD SYBR qPCR Mix
was used for quantitative real-time RT-PCR analysis of
each gene’s expression. The following primers (Invitrogen,
California, USA) were used: AdipoR1 forward, TGAGG
TACCA GCCAGATGTC; AdipoR1 reverse, CGTGTCC
GCT TCTCTGTTAC; FAS forward, GGAACTGAAC GG
CATTACTC G; FAS reverse, CATGCCGTTA TCAACTT
GTC C; SREBP-1 forward, CCACCCTGTA GGTCACCGTT T; SPEBP-1 reverse, GTGGGTATAA GCGTTCAGCT
GC; β-actin forward, GGGAAATCGT GCGTGACATT;
and β-actin reverse, GCGGCAGTGG CCATCTC. The
amplification was performed as follows: 95°C for 1 min
followed by 40 cycles of 95°C for 15 s, 60°C for 32 s, 95°C
for 15 s, 60°C for 20 s, and 95°C for 15 s with a real-time
PCR system (ABI Prism 7000). The data were normalized
to β-actin.
Knockdown with small interfering RNA (siRNA)
H4IIE cells were seeded in a six-well plate at 2 × 105
cells per well in 2 ml of antibiotic-free normal growth
medium supplemented with FBS. Subconfluent cells
were transfected with AdipoR1 siRNA or control siRNA
(Santa Cruz Biotechnology) in 1 ml Opti-MEM (GIBCO,
USA) containing a transfection reagent mixture of
Reagent A and B (Santa Cruz Biotechnology, USA) for
7 h. Then, 1 ml of 2 × normal growth medium was added.
After a 24-h incubation, the normal growth medium was
used for another 48 h according to the manufacturer’s in-
structions. The transfection efficiency was assessed by
qRT-PCR, followed by treatment with isoquercitrin.
Statistical analysis
Data for individual groups were presented as the mean ±
standard error of the mean (SEM) and were statistically
analyzed using Dunnett or Tukey test. Values between
two groups were analyzed by Student’s t-test. Differences
were considered significant for P < 0.05.
Results
Isoquercitrin inhibits lipid accumulation in FFA-induced
H4IIE cells
Cells were cultured with different concentrations of iso-
quercitrin (50, 100, and 200 μM) for 72 h, and cell via-
bility was determined by the MTT assay. As expected,
isoquercitrin did not show significant cytotoxic effects
(Figure 1A). Thereafter, all indicated doses of isoquerci-
trin were chosen to investigate the effect of isoquercitrin
on lipid accumulation in H4IIE cells. Subconfluent
H4IIE cells were incubated in medium containing the in-
dicated concentrations of isoquercitrin for 24 h, followed
by adding 0.1 mM FFA for another 24 h. The total lipid
levels were detected by Oil Red O staining. As shown in
Figure 1B and C, isoquercitrin treatment significantly
prevented cellular lipid droplet accumulation in H4IIE
cells in a dose-dependent manner.
Isoquercitrin increases phosphorylation of AMPKα in
H4IIE cells
To assess the effect of isoquercitrin on phosphorylation
of AMPKα that was the possible mechanism responsible
for the lipid accumulation, H4IIE cells were treated with
isoquercitrin (50, 100, and 200 μM) for 12 h. As Thr172
Figure 1 Effects of isoquercitrin on cell survival and lipid accumulation in H4IIE cells with FFA. (A) H4IIE cells were exposed to various
doses of isoquercitrin, and cell viability was measured by MTT tests. Values are expressed as the percentage of the control, which was taken as
100%, and shown as the mean ± SEM (n = 3). (B) and (C) Cells were cultured in the absence or presence of isoquercitrin (50, 100, and 200 μM) for
24 h, followed by stimulation with or without FFA (0.1 mM) for another 24 h. (B) Intracellular oil droplets were visualized by Oil Red O staining
under a microscope at 200 × original magnification. (C) Quantitative analysis of lipid deposition was measured by optical density (OD) values at
540 nm after staining. Values are presented as a dose-dependent decrease and expressed as mean ± SEM (n = 3). **P < 0.01 compared to FFA-treated
control group.
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AMPK activity, and ACC is its primary downstream
targeting enzyme. The phospho-Thr172 antibody of
AMPKα and the phospho-Ser79 antibody of ACC were
examined by immunoblotting to assess AMPK activa-
tion. Isoquercitrin significantly increased the level of
pAMPKα over the untreated control, but the expression
of endogenous total AMPKα protein showed almost no
change (Figure 2A). Moreover, isoquercitrin stimulated
phosphorylation of ACC (Ser79), whereas the overall
ACC protein expression did not change (Figure 2A).
This result indicated that isoquercitrin enhanced the
phosphorylation of AMPK and ACC (Figure 2B and C).
Isoquercitrin downregulates SREBP-1 and FAS mRNA
expressions in H4IIE cells
Many reports have shown that AMPK decreases the
actions of the transcriptional factor SREBP-1 and sup-
presses the expression of lipogenic genes, including FAS
[15]. Because isoquercitrin enhanced phosphorylation of
AMPK and stimulated ACC phosphorylation, the effectsof isoquercitrin on the gene expression of SREBP-1 and
FAS in H4IIE cells were evaluated by real-time PCR ana-
lysis. H4IIE cells treated with isoquercitrin showed signifi-
cantly decreased SREBP-1 and FAS mRNA expressions
(Figure 3A and B).
AMPK pathway regulates isoquercitrin-induced reduction
of lipid levels in H4IIE cells
Because isoquercitrin increased the phosphorylation of
AMPK and ACC, and reduced the gene expression levels
of SREBP-1 and FAS in H4IIE cells, we investigated the
critical role of AMPK signaling on isoquercitrin-mediated
hepatic fatty acid metabolism using an AMPK inhibitor,
compound C. Pretreatment of compound C significantly
decreased the AMPK phosphorylation stimulated by
isoquercitrin (Figure 4A). In addition, compound C sig-
nificantly attenuated the mRNA expression of FAS in-
duced by isoquercitrin in H4IIE cells (Figure 4B). These
results indicate that AMPK plays a crucial role in the
effect of isoquercitrin in regulating lipid metabolism in
H4IIE cells.
Figure 2 Isoquercitrin stimulates phosphorylation of AMPK and ACC in H4IIE cells. Cells were incubated with various concentrations of
isoquercitrin or control for 12 h. (A) Total cell lysates were subjected to Western blot analysis with antibodies for phosphorylated AMPKα and
ACC, total AMPKα, and ACC in H4IIE cells. (B) and (C) Values are shown as mean ± SEM (n = 3). *P < 0.05; **P < 0.01 compared to control group.
Figure 3 Isoquercitrin decreases the mRNA expression levels of SREBP-1 and FAS in H4IIE cells. Cells were treated with the indicated
concentrations of isoquercitrin for 12 h. The mRNA expression levels of SREBP-1 (A) and FAS (B) were assessed by quantitative real-time PCR.
Results are expressed as means ± SEM (n = 3) normalized to β-actin mRNA expression. *P < 0.05; **P < 0.01 compared to control group.
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Figure 4 AMPK inhibitor attenuates isoquercitrin-mediated FAS mRNA expression in H4IIE cells. H4IIE cells were incubated with
isoquercitrin (200 μM) in the absence or presence of compound C (10 μM) pretreatment for 1 h. (A) Isoquercitrin-induced AMPK activation was
suppressed by compound C. (B) The mRNA expression level of FAS was analyzed as indicated. Values are expressed as mean ± SEM (n = 3).
**P < 0.01 between control and isoquercitrin without compound C, ##P < 0.01 between isoquercitrin with or without compound C.
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AMPK in H4IIE cells
Next, we studied whether isoquercitrin could regulate Adi-
poR1 mRNA expression levels in H4IIE cells by using real-
time PCR. As expected, AdipoR1 mRNA expression in
H4IIE cells was dose-dependently increased by isoquercitrin
treatment (Figure 5A). Because isoquercitrin affects both
the AdipoR1 mRNA expression level and AMPK phosphor-
ylation, we investigated whether isoquercitrin stimulates the
expression of AdipoR1 to result in AMPK activation, or if
phosphorylating AMPK leads to an increase in AdipoR1
expression. First, we examined the effect of AMPK phos-
phorylation mediated by isoquercitrin on AdipoR1 mRNA
expression levels by using the AMPK agonist AICAR and
the AMPK inhibitor compound C. The results showed that
the mRNA expression level of AdipoR1 was significantly in-
creased by AICAR treatment in the H4IIE cells (Figure 5B).
Pretreatment of H4IIE cells with compound C significantly
suppressed the isoquercitrin-induced increase in AdipoR1
mRNA expression compared with AICAR treatment, which
acted as a positive control (Figure 5C). These findings indi-
cated that isoquercitrin might regulate the AdipoR1 mRNA
expression level via AMPK.
Isoquercitrin affects AMPK signaling after AdipoR1
knockdown in H4IIE cells
To evaluate whether isoquercitrin enhances AMPK phos-
phorylation without regulating AdipoR1, H4IIE cells weretransfected with scrambled siRNAs, which served as the
control, or with specific siRNAs against AdipoR1. After
transfection, AdipoR1 mRNA expression in H4IIE cells
was remarkably reduced when compared with the control,
suggesting that the knockdown was effective (Figure 6A).
The transfection of AdipoR1 siRNA in H4IIE cells did not
alter AMPK activation stimulated by isoquercitrin treat-
ment compared with the control group (Figure 6B).
Discussion
AMPK is a master regulator and a major cellular energy
sensor of metabolic homeostasis. Defects in AMPK are
associated with metabolic disorders. The increase in the
prevalence of lipid metabolic disorders has become a
major global public health problem and plays a large role
in the subsequent development of NAFLD. Therefore,
there has been a worldwide focus on developing preven-
tion methods and therapeutics that target lipid metabolic
disorder and NAFLD. Recently, researchers have focused
on the clinical effects of dietary compounds from plants,
which are known to possess biological properties that re-
duce the risk of metabolic disorders. Previous in vivo
and in vitro studies have suggested that several flavo-
noids, such as tiliroside, luteolin, and cathechins, act to
manage metabolic disorders. Some of the main effects of
these dietary compounds are on hepatic lipid metabol-
ism via AMPK activation and FAS gene expression
[13,16,17]. In the present study, we demonstrate that
Figure 5 Isoquercitrin increases AdipoR1 mRNA expression levels via AMPK in H4IIE cells. (A) Cells were treated with different
concentrations of isoquercitrin as mentioned. (B) H4IIE cells were treated with AICAR (0.5 mM and 1 mM) for 12 h as indicated. (C) H4IIE cells
were treated with isoquercitrin (200 μM) or AICAR (1 mM) for 12 h in the absence or presence of preincubation with 10 μM compound C for 1 h.
The mRNA expression levels of AdipoR1 were measured by quantitative real-time PCR and normalized to β-actin mRNA expression. Values are
shown as means ± SEM (n = 3). (A) *P < 0.05; **P < 0.01 compared to control group. (B) *P < 0.05; **P < 0.01 compared to control group.
(C) **P < 0.01 between isoquercitrin and control group, ##P < 0.01 between AICAR and control group, N.S. between isoquercitrin and isoquercitrin
plus compound C.
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pathway to inhibit lipid accumulation in H4IIE cells.
Thus, isoquercitrin may be a novel dietary flavonoid that
can suppress the development of lipid metabolic dis-
order and NAFLD.
Numerous studies have indicated that AMPK is a key
cellular energy sensor, which plays an important role in
regulating the liver and whole-body lipid metabolic
homeostasis. In many reports, it has been proved that
the extent of phosphorylation of Thr172 reflects the de-
gree of AMPK activation, which is necessary and suffi-
cient for AMPK activity [18,19]. The first downstream
enzymatic target of AMPK is ACC, which is related to
the synthesis of malonyl-CoA. ACC is involved with pro-
moting fatty acid biosynthesis and inhibiting fatty acid
oxidation. The suppression of ACC activation by AMPK
phosphorylation causes a rate-controlling decrease in
malonyl-CoA, followed by a decrease in fatty acidsynthesis and an increase in fatty acid oxidation. It also
has been reported that phosphorylation of ACC at Ser77
and Ser79 participate in the control of ACC activity [20].
The present study showed that isoquercitrin treatment
significantly stimulated AMPK activation and increased
the phosphorylation of ACC.
SREBP-1c is a transcription factor, which stimulates
fatty acid biosynthesis in the liver by regulating several
lipogenic enzymes, such as FAS and ACC. In addition, it
has been reported that the expression of SREBP-1 is
markedly altered in the liver of obese patients and in the
fatty livers of obese mice [2,21]. The action of SREBP-1
is suppressed by AMPK activation and mediates inhib-
ition of ACC and FAS gene expression to regulate liver
lipid metabolism in animal models [1]. In addition, some
insulin-sensitizing drugs activate AMPK and subse-
quently, reduce hepatic levels of SREBP-1 and lipogenic
gene expression in hepatocytes [3].
Figure 6 AdipoR1 knockdown does not change isoquercitrin-induced AMPK signaling in H4IIE cells. H4IIE cells were transfected with
AdipoR1 siRNA or control siRNA as indicated, followed by isoquercitrin treatment for 12 h. (A) After transfection, AdipoR1 expression was
determined by quantitative RT-PCR. (B) Phosphorylation and total AMPKα protein expression were measured by Western blotting. Results were
analyzed and shown as means ± SEM (n = 3). #P < 0.05 between isoquercitrin and control plus AdipoR1 siRNA.
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that isoquercitrin treatment induced a reduction in
SREBP-1 mRNA expression levels and a downregulation
of its target lipogenic gene FAS in H4IIE cells. Further-
more, pretreatment with compound C reversed the
isoquercitrin-mediated decrease in FAS mRNA expres-
sion and inhibition of lipid deposition. These observa-
tions implied that the enhancement of AMPK activation
by isoquercitrin leads to suppression of SREBP-1 and
FAS gene expressions, resulting in the isoquercitrin-
induced reduction in fatty acid accumulation in H4IIE
cells.
AdipoR1 and AdipoR2, two major physiological recep-
tors for adiponectin, have been reported to play critical
roles in lipid and glucose metabolism [22]. Increasing
the expression levels of AdipoR1 and AdipoR2 in the
liver of mouse models of obesity and type 2 diabetes can
improve insulin resistance and diabetes. Moreover, the
disruption of AdipoR1 and AdipoR2 almost completely
abolished adiponectin binding in the liver, leading to an
increase in triglyceride content, oxidative stress, and
inflammation, which resulted in NAFLD and insulin re-
sistance. In addition, it has been reported that the ex-
pression levels of AdipoR1 and AdipoR2 are significantly
decreased in NAFLD animal models [23]. A recent re-
port showed that disruption of AdipoR1 and AdipoR2 in
mice caused the mice to be more vulnerable to insulin
resistance than adiponectin-knockout mice. This result
indicates that the expressions of AdipoR1 and AdipoR2may be regulated by more than adiponectin binding and
adiponectin actions [22]. AdipoR1 has been found to be
involved in activating the AMPK pathway, which mediates
lipid metabolism in the liver and regulates globular
adiponectin-stimulated AMPK activation in hepatocytes
[24]. These studies suggest that increasing AdipoR1 will
be a novel prevention approach for metabolism disorders.
Previous studies reported that AdipoR expression is reg-
ulated by hormones, cytokines, and metabolism factors,
and it is also modified by adiponectin, FFA, the liver X
receptor, and Peroxisome proliferator-activated receptor
alpha (PPAR-α) and peroxisome proliferator-activated
receptor gamma (PPAR-γ) agonists [25-27]. Recently, sev-
eral flavonoids have been reported to regulate the expres-
sion of AdipoR1 and AMPK [28,29]. However, it was
unknown whether isoquercitrin affects hepatic AdipoR1
mRNA expression and whether AMPK mediates fatty acid
metabolism. In this study, we demonstrate that isoquerci-
trin upregulated the mRNA expression level of AdipoR1
and stimulated AMPK phosphorylation to inhibit lipid ac-
cumulation in H4IIE cells.
Many studies have shown that AdipoR1 is tightly re-
lated to activating downstream steps in the AMPK path-
way to inhibit hepatic fatty acid synthesis and increase
fatty acid oxidation. Interestingly, the results of the
present study suggest that AMPK activation also in-
creases the mRNA expression level of AdipoR1. The
AMPK inhibitor decreased isoquercitrin-induced FAS
expression and lipid deposition in H4IIE cells, implying
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Meanwhile, isoquercitrin increased AdipoR1 expression
without adiponectin stimulation, whereas pretreatment
with the AMPK inhibitor attenuated the isoquercitrin-
mediated increase in AdipoR1 expression levels. In
addition, the AMPK agonist AICAR significantly stimu-
lated the mRNA expression level of AdipoR1. Therefore,
it seems that isoquercitrin acts as an AMPK activator af-
fecting the expression of AdipoR1, which is consistent
with the stimulatory effect of the PPARα agonist on the
regulation of AdipoR2 expression in liver cells [30,31].
Furthermore, our results demonstrate that isoquerci-
trin activated AMPK compared with the control group
in an experiment using transfection of AdipoR1 siRNA
in H4IIE cells, which indicates that the main effect of
isoquercitrin is on AMPK activation. Thus, by acting as
AMPK activator, isoquercitrin may regulate AMPK acti-
vation, leading to improve AdipoR1 expression in H4IIE
cells. These data show, for what we believe is the first
time, that AMPK agonists may increase the mRNA ex-
pression level of AdipoR1. This result requires further
confirmation in the future.Conclusions
The present study indicates the novel finding that isoquer-
citrin, a dietary flavonoid in herbs, flowers, and vegetables,
activates the AMPK signaling pathway in H4IIE cells. Iso-
quercitrin appeared to stimulate AMPK activation, which
enhanced AdipoR1 expression, suppressed SREBP-1 and
FAS expressions in H4IIE cells, and resulted in the regula-
tion of fatty acid metabolism. These findings provide cel-
lular molecular evidence demonstrating that isoquercitrin
can potentially be used as a novel dietary compound to
prevent lipid metabolism disorder and NAFLD. These re-
sults need to be investigated in further in vivo studies.Abbreviations
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